RETEVMO
GrowthNDAORALCAPSULE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETEVMO (selpercatinib) is an oral, selective RET inhibitor approved in April 2024 for treating RET-altered cancers across multiple solid tumor types. It works by blocking the Rearranged during Transfection (RET) kinase, which drives tumor growth in patients with RET gene fusions or mutations. This precision medicine targets a genetically defined patient population with high unmet need.
$58MPart D
GrowthGrowing
12.4 years to LOEEarly-stage growth asset with significant runway; commercial team is ramping up market access and patient education to capture RET-fusion population.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RETEVMO represents a high-value precision oncology career opportunity within a fast-growing, well-funded Eli Lilly franchise. Early-stage product lifecycle offers substantial scope to build market awareness, establish treatment algorithms, and drive patient identification in an underserved RET-fusion population.
Brand ManagerMedical Science Liaison (MSL)
Worked on RETEVMO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.